Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant
about
Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activityHIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factorsPrototype foamy virus Bet impairs the dimerization and cytosolic solubility of human APOBEC3GHIV-1 Vif, APOBEC, and intrinsic immunityAPOBEC3G-UBA2 fusion as a potential strategy for stable expression of APOBEC3G and inhibition of HIV-1 replicationHuman cytidine deaminase APOBEC3H restricts HIV-1 replicationA single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivityBlocking HIV-1 transmission in the female reproductive tract: from microbicide development to exploring local antiviral responsesThe APOBEC3 family of retroelement restriction factorsSuppression of APOBEC3-mediated restriction of HIV-1 by VifMulti-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapyAPOBEC3G: an intracellular centurionVpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded VifLentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity.In vivo HIV-1 hypermutation and viral loads among antiretroviral-naive Brazilian patients.Characterization of RNA binding and chaperoning activities of HIV-1 Vif protein. Importance of the C-terminal unstructured tail.Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification.Insights into the dual activity of SIVmac239 Vif against human and African green monkey APOBEC3G.Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity.Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllersCharacterization of anti-HIV activity mediated by R88-APOBEC3G mutant fusion proteins in CD4+ T cells, peripheral blood mononuclear cells, and macrophages.The HDAC6/APOBEC3G complex regulates HIV-1 infectiveness by inducing Vif autophagic degradation.APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo.Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment.Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif.Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif proteinHost restriction factors in retroviral infection: promises in virus-host interaction.Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formationHIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes.APOBEC3G impairs the multimerization of the HIV-1 Vif protein in living cells.Functional domain organization of human APOBEC3G.Differential sensitivity of "old" versus "new" APOBEC3G to human immunodeficiency virus type 1 vif.APOBEC3G-independent reduction in virion infectivity during long-term HIV-1 replication in terminally differentiated macrophagesVif and Apobec3G in the innate immune response to HIV: a tale of two proteins.APOBEC proteins and intrinsic resistance to HIV-1 infectionOptimal translation initiation enables Vif-deficient human immunodeficiency virus type 1 to escape restriction by APOBEC3G.
P2860
Q24565021-C9017AE8-464C-4A65-9553-E4F9E81E2C3DQ24619114-FCCFE26A-9444-473B-B5C3-082B84B3F990Q24629953-3AFEB1D8-4355-4E55-8BFE-EFE811B31AA4Q24647833-E1A8EE80-8064-4575-AD6B-F83C53D95627Q24651400-8C4B29BF-F8C2-47CC-BB85-0CBE64350502Q24653682-52344A67-02BC-4823-8632-0982258AA4FEQ24656551-CFD0B498-8111-47AD-88C6-70B4A28C8CE6Q26774878-4E9F421B-4CB1-420B-973C-6838CD1EF4C2Q26862780-D98952E5-0415-4B77-A9F8-AD8FA41F0EC3Q27025150-D46F00AE-8E86-4562-A2DC-C9C739453637Q28480578-819D3B78-C650-47C5-82DF-6B5B0CB62A29Q28754989-581AD856-B39F-4C1D-88D0-6A8445B5D026Q33328499-17D2FE4D-C9D3-4255-8C0B-59BF266ECE0DQ33349452-31B7884F-A089-4D2A-B198-07A0239622DDQ33654949-7A326EBE-60A1-44F1-8CFA-7395FEBD78E4Q33826857-30B891ED-9ABB-4029-9D0B-07758377112FQ34045987-AE15A584-B27D-47EB-9AE4-ADC7CEF8756FQ34116867-6AC5183A-8C12-4A78-903F-46FB19B801C2Q34266485-0D137386-72EB-44AA-9539-33ACAB63D71AQ34412763-2C155F2F-2D9E-4B9C-8485-390A09A006DCQ34493717-5214857B-AA1C-40C2-9CEC-1E439CB73248Q34742607-41478B96-6D7B-48F3-970A-727E078E062AQ35489088-0686E819-B1B1-46D4-92CC-45FC613EDC71Q35496476-6E853FE9-92F2-4D9A-ACC9-BD8A51B4753BQ35776289-937CEC8E-BE9C-465C-BA92-8A41953C803DQ36019696-EFB47E8A-F060-49D4-8E4F-BC8813FB1BBBQ36156679-917048ED-8B0C-41AA-BF3F-3C055B25DD5FQ36249419-F99B8F41-886D-4FB6-83E7-37F9CAEA707CQ36315163-E0195F6D-450E-4435-8AED-2D9C628E5187Q36432758-EA2D8D98-9E76-4B36-8311-C91329521343Q36548179-FC180A81-D61F-4A20-AB32-C21E28DAA3E4Q36666251-C77A52DD-2393-4F89-874E-AED72E5309E1Q36677709-A50F616A-B85F-472C-8378-82E4C7A8E9D7Q36827236-A48D679B-EB2E-4DEA-8EF0-53B38B55964BQ37012852-B756499F-F060-4DD5-9772-53ED83A268C5Q37033381-8842BA3B-6673-4911-9CEC-679B3F1D58B4Q37039316-FD14117B-5047-4119-8864-DE45F8448088Q37119030-FCB964FE-EC7C-4CEB-9F69-119FFF446AACQ37140468-945A8BED-5B59-4F99-B288-5ACDD9B8C3DFQ37191968-C62B0F71-E360-4604-A4C4-461895E3483E
P2860
Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Human immunodeficiency virus t ...... ion-resistant APOBEC3G variant
@ast
Human immunodeficiency virus t ...... ion-resistant APOBEC3G variant
@en
type
label
Human immunodeficiency virus t ...... ion-resistant APOBEC3G variant
@ast
Human immunodeficiency virus t ...... ion-resistant APOBEC3G variant
@en
prefLabel
Human immunodeficiency virus t ...... ion-resistant APOBEC3G variant
@ast
Human immunodeficiency virus t ...... ion-resistant APOBEC3G variant
@en
P2093
P2860
P356
P1433
P1476
Human immunodeficiency virus t ...... ion-resistant APOBEC3G variant
@en
P2093
Eri Miyagi
Hiroaki Takeuchi
Klaus Strebel
Mohammad A Khan
Ritu Goila-Gaur
Sandra Kao
Sandrine Opi
P2860
P304
P356
10.1128/JVI.02694-06
P407
P577
2007-05-23T00:00:00Z